Skip to main
NYXH

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah is making strong progress in its Genio system launch in the U.S., with a doubling of active high-volume accounts in the quarter and continued rollout of its Genio app software upgrade. The company's focused efforts on reimbursement, including pursuing a new CPT code, bode well for future growth potential. With Q2 net-revenue in line with pre-announced figures and a positive FY26 revenue guidance above market expectations, we remain optimistic about Nyxoah's potential and reiterate an OW rating.

Bears say

Nyxoah is dealing with increased competition and lower than expected financials for the second quarter, with slower revenue growth than expected. Additionally, the company's gross margin and opex spend were both above estimates, and the company has yet to reach its previously stated net revenue and gross margin guidance for FY26. The company's overall high valuation in the medtech category is also contributing to a lowered price target of $7 as a result of a lower valuation multiple applied to FY27 revenue forecast.

Nyxoah SA (NYXH) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 3 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of Sep 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.